ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,537.02
      0.51%
      US Tech 100
      19,641.60
      0.83%
      Dow Jones
      39,308.00
      -0.06%
      Brent Oil
      86.995
      0.10%
      Bitcoin
      57,298.12
      -4.76%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Axovant Gene Therapies Ltd (AXGT)

      7. Axovant Gene Therapies Ltd (AXGT) News

      AXGT

      Axovant Gene Therapies (AXGT)

      Axovant Gene Therapies Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:AXGT
      DateTimeSourceHeadlineSymbolCompany
      03/26/20204:16PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
      03/02/20207:42AMEdgar (US Regulatory)Information Statement - All Other (definitive) (def 14c)NASDAQ:AXGTAxovant Gene Therapies Ltd
      02/28/20206:07AMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:AXGTAxovant Gene Therapies Ltd
      02/25/202011:19AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AXGTAxovant Gene Therapies Ltd
      02/24/20204:01PMGlobeNewswire Inc.Axovant Gene Therapies Announces Closing of $74.7 Million Public Offering of Common Shares and Prefunded Warrants, Including ...NASDAQ:AXGTAxovant Gene Therapies Ltd
      02/21/20205:17PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
      02/21/20206:04AMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:AXGTAxovant Gene Therapies Ltd
      02/19/202010:11PMGlobeNewswire Inc.Axovant Gene Therapies Announces Pricing of $65 Million Public OfferingNASDAQ:AXGTAxovant Gene Therapies Ltd
      02/19/20205:36PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:AXGTAxovant Gene Therapies Ltd
      02/19/20205:29PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:AXGTAxovant Gene Therapies Ltd
      02/19/20204:02PMGlobeNewswire Inc.Axovant Gene Therapies Announces Commencement of Public OfferingNASDAQ:AXGTAxovant Gene Therapies Ltd
      02/19/20207:32AMEdgar (US Regulatory)Proxy Statement - Other Information (preliminary) (pre 14c)NASDAQ:AXGTAxovant Gene Therapies Ltd
      02/19/20206:06AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
      02/13/202012:44PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AXGTAxovant Gene Therapies Ltd
      02/11/202012:17PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AXGTAxovant Gene Therapies Ltd
      02/10/20206:47AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AXGTAxovant Gene Therapies Ltd
      02/10/20206:47AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
      02/10/20206:00AMGlobeNewswire Inc.Axovant Announces Financial Results for Third Fiscal Quarter and Nine Months Ended December 31, 2019NASDAQ:AXGTAxovant Gene Therapies Ltd
      01/13/20206:30AMGlobeNewswire Inc.Axovant Announces Positive 12-month Data on AXO-Lenti-PD and Provides Updates Across Gene Therapy Pipeline ProgramsNASDAQ:AXGTAxovant Gene Therapies Ltd
      12/19/20195:41PMGlobeNewswire Inc.Axovant Provides Clinical Program Update for AXO-AAV-GM1, a Novel Investigational Gene Therapy for GM1 GangliosidosisNASDAQ:AXGTAxovant Gene Therapies Ltd
      12/03/20197:00AMGlobeNewswire Inc.Axovant Announces Amendment to Credit Facility with Hercules CapitalNASDAQ:AXGTAxovant Gene Therapies Ltd
      11/18/20197:30AMGlobeNewswire Inc.Axovant Gene Therapies Receives Orphan Drug Designation from FDA for AXO-AAV-GM1 for the Treatment of GM1 GangliosidosisNASDAQ:AXGTAxovant Gene Therapies Ltd
      11/08/20194:54PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
      11/08/20198:04AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
      11/08/20198:03AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AXGTAxovant Gene Therapies Ltd
      11/08/20198:00AMGlobeNewswire Inc.Axovant Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2019NASDAQ:AXGTAxovant Gene Therapies Ltd
      11/05/20198:00AMGlobeNewswire Inc.Axovant Gene Therapies Announces Investor Conference Presentations for the Remainder of 2019NASDAQ:AXGTAxovant Gene Therapies Ltd
      10/23/20197:03AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
      10/23/20197:00AMGlobeNewswire Inc.Axovant Presents First Evidence of Clinical Stabilization in Tay-Sachs Disease at the European Society of Gene and Cell Thera...NASDAQ:AXGTAxovant Gene Therapies Ltd
      10/10/20198:00AMGlobeNewswire Inc.Axovant Gene Therapies Announces Upcoming Presentations at the European Society of Gene and Cell Therapy 27th Annual Congress...NASDAQ:AXGTAxovant Gene Therapies Ltd
       Showing the most relevant articles for your search:NASDAQ:AXGT

      Your Recent History

      BIT
      BAY
      Bayer
      BIT
      UC8NVH
      Unicredit Bank
      Delayed Upgrade Clock